---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-019498"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T18:51:39.889710+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Edgewise Therapeutics reports Q4 2024 net loss of $39.7M; pipeline milestones on track

## Summary
- Net loss $39.7M ($0.42 per share) for Q4 2024; cash and equivalents $470.2M as of Dec 31, 2024.
- Completed GRAND CANYON enrollment (175 adults) for sevasemten in Becker; topline data expected Q4 2026.
- Positive Phase 2 CANYON topline results for sevasemten in Becker; plan to discuss FDA filing in H1 2025.
- On track to report CIRRUS-HCM Phase 2 data in Q1 2025 and LYNX/FOX Duchenne data in H1 2025.

## SEC filing metadata
- accession: 0001104659-25-019498
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465925019498/0001104659-25-019498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465925019498/tm257448d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-019498
- JSON: https://secwatch.observer/filing/0001104659-25-019498.json
- Plain text: https://secwatch.observer/filing/0001104659-25-019498.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.